A Randomized Open Label Trial Evaluating the Efficacy of AEMCOLO (Rifamycin SV MMX) in the Treatment of Small Intestinal Bacterial Overgrowth (SIBO)

Who is this study for? Adult patients with small intestinal bacterial overgrowth
What treatments are being studied? AEMCOLO (Rifamycin SV MMX)
Status: Enrolling by invitation
Location: See location...
Intervention Type: Drug
Study Type: Interventional
Study Phase: Phase 2
SUMMARY

Open label interventional randomized pilot study utilizing two dosing regimens of AEMCOLO. The goal of this study is to evaluate effectiveness of a novel antibiotic, AEMCOLO (Rifamycin SV MMX) in the treatment of Small intestinal bacterial overgrowth (SIBO).

Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Maximum Age: 70
Healthy Volunteers: Accepts Healthy Volunteers
View:

• Symptoms compatible with SIBO

• A positive breath test for either hydrogen predominant, methane predominant or mixed SIBO

Locations
United States
New York
The New York Center for Travel and Tropical Medicine
New York
Time Frame
Start Date: June 30, 2020
Estimated Completion Date: December 30, 2022
Participants
Target number of participants: 30
Treatments
Experimental: 1st regimen
15 patients will receive AEMCOLO (Rifamycin SV MMX) 194 mg two tablets to take twice daily for 14 days (56 Tablets)
Experimental: 2nd regimen
15 patients will receive AEMCOLO (Rifamycin SV MMX) 194 mg tablets to take two tablets three times daily for 14 days (84 Tablets).
Related Therapeutic Areas
Sponsors
Leads: Bradley Connor

This content was sourced from clinicaltrials.gov

Similar Clinical Trials